Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-03-01
2011-03-01
Robinson, Hope A. (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C435S007100
Reexamination Certificate
active
07897727
ABSTRACT:
Implantable devices for adhering eukaryotic cells and devices providing a substrate for eukaryotic cell growth and/or differentiation in vitro are described. Each device comprises a scaffold that is coated with a protein comprising an adhesive polypeptide that has at least 90% sequence identity to a specific peptide sequence within domain IV of perlecan. The devices adhere epithelial cells, epithelial stem cells, mesenchymal stem cells, and osteoblasts.
REFERENCES:
patent: 6262017 (2001-07-01), Dee et al.
patent: 7081345 (2006-07-01), Roecklin et al.
patent: 7510843 (2009-03-01), Roecklin et al.
patent: 2004/0009474 (2004-01-01), Leach et al.
patent: WO 01/90366 (2000-05-01), None
Chakravarti, et al., “Recombinant Domain III of Perlecan Promotes Cell Attachment Through Its RGDS Secquence,”The Journal of Biological Chemistry, Jan. 1995, 270(1), pp. 404-409.
Cohen, et al., “Structural Characterization of the Complete Human Perlecan Gene and Its Promoter,”Proc. Natl. Acad. Sci. USA, Nov. 1993, vol. 90, pp. 10404-10408.
Hopf, et al., “Recombinant Domain IV of Perlecan Binds to Nidogens, Laminin-Nidogen Complex, Fibronectin, Fibulin-2 and Heparin,”Eur. J. Biochem, 1999, vol. 259, pp. 917-925.
Hopf, et al., “Mapping of Binding Sites for Nidogens, Fibulin-2, Fibronectin and Heparin to Different IG Modules of Perlecan,”J. Mol. Biol., 2001, vol. 311, pp. 529-541.
Iozzo, Renato V.; “Matrix Proteoglycans: From Molecular Design to Cellular Function,”Annu. Rev. Biochem., 1998, vol. 67, pp. 609-652.
Hayashi, et al., “Endothelial Cells Interact with the Core Protein of Basement Membrane Perlecan through β1 and β2 Integrins: An Adhesion Modulated by Glycosaminoglycan,”The Journal of Cell Biology, Nov. 1992, 119(4), pp. 945-959.
Lebaron, Richard G. and Athanasiou, Kyriacos A., “Extracellular Matrix Cell Adhesion Peptides: Functional Applications in Orthodpedic Materials,”Tissue Engineering, 2000, vol. 6(2) pp. 85-103.
Massia, S.P., Hubbell, J.A.; “Human endothelial cell interactions with surface-coupled adhesion peptides on a nonadhesive glass substrate and two polymeric biomaterials,” Journal of Biomedical Materials Research, 1991, vol. 25, No. 2, pp. 223-242.
Murdoch, et al., Primary Structure of the Human Heparan Sulfate Proteoglycan from Basement Membrane (HSPG2/Perlecan),The Journal of Biological Chemistry, Apr. 25, 1992, vol. 267, No. 12, pp. 8544-8577.
Newton, et al., “Residues on Both Faces of the First Immunoglobulin Fold Contribute to Homophilic Binding Sites of PECAM-1/CD31,”The Journal of Biological Chemistry, 272(33), Aug. 15, 1997, pp. 20555-20563.
Noonan, et al., “The Complete Sequence of Perlecan, a Basement Membrane Heparan Sulfate Proteoglycan, Reveals Extensive Similarity with Laminin A Chain, Low Density Lipoprotein-Receptor, and the Neural Cell Adhesion Molecule.”The Journal of Biological Chemistry, 266(34), Dec. 5, 1991, pp. 22939-22947.
Puleo, D.A., “Immobilization of Protein on Silanized Orthopedic Biomaterials,”Materials Research Society Symposium, 1994, vol. 331, pp. 269-275.
Seffernick, et al., “Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different,”Journal of Bacteriology, Apr. 2001, vol. 183, pp. 2405-2410.
Sharma, et al., “Antisense Targeting of Perlecan Blocks Tumor Growth and Angiogenesis in Vivo,”J. Clin. Invest., Oct. 1998, vol. 102, No. 8, pp. 1599-1608.
Sundarraj, et al., “Perlecan is a Component of Cartligae Matrix and Promotes Chondrocyte Attachment,”Journal of Cell Science, 1995, vol. 108, pp. 2663-2672.
Sweigert, et al., “Review: Toward Tissue Engineering of the Knee Meniscus,”Tissue engineering, 7(2), 2001, pp. 111-129.
Weismann, et al., “Ligand-binding sites in lg-like domains of receptor tyrosine kinases,”J. Mol. Med. 78:247-260 (2000).
Wells, James A., “Additivity of Mutational Effects in Proteins,”Biochemistry, Sep. 18, 1990, vol. 29, No. 37, pp. 8509-8517.
Mikos, Antonios G. et al., “Biomaterials for Drug and Cell Delivery,” Materials Research Society Symposium Proceedings; Materials Research Society 1994; materials Research Society, Pittsburg, Pennsylvania; vol. 331; pp. 269-275.
NIH-MGC, National Institutes of Health, Mammalian Gene Collection (MGC), Sep. 2000, Acc. No. BE747501.
NIH-MGC, National Institutes of Health, Mammalian Gene Collection (MGC), Jul. 2000, Acc. No. BE291062.
Carson Daniel D.
Farach-Carson Mary C.
Safran Jeffrey B.
RatnerPrestia
Robinson Hope A.
University of Delaware
LandOfFree
Bioactive peptide for cell adhesion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bioactive peptide for cell adhesion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bioactive peptide for cell adhesion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2762560